Essex Woodlands raises $360M for new life sciences fund

Essex Woodlands is making progress with its ninth life sciences fund. The group noted in an SEC filing that it has raised $360 million of a planned $750 million fund, up from the $221 million it had raised and then reported last year. But there's still a long way to go for Essex Woodlands as it follows up on Fund VIII, which closed 6 years ago with $900 million. The global group--with offices in London, Palo Alto, Houston, New York and Shanghai--invests in drugs, devices and service companies. More

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.